Peptidase inhibitor 16: a new biomarker for human Treg

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1003185

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

As autoimmune diseases including type 1 diabetes and IBD are on the increase, there is still great need for novel diagnostic or therapeutic molecules. We have discovered a novel role for a protein called PI16, which we believe is a biomarker for natural regulatory T cells. These cells police the immune system, preventing inappropriate immune responses such as those that cause autoimmune diseases. This project will confirm its suitability for use as a diagnostic or therapeutic biomarker.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: NHMRC Project Grants

Funding Amount: $391,262.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

autoimmune disease | biological markers | cellular interactions | mechanism of action | molecular immunology | novel therapeutic agents

Related Links